153 related articles for article (PubMed ID: 27456700)
21. Simvastatin prescribing patterns before and after FDA dosing restrictions: a retrospective analysis of a large healthcare claims database.
Tuchscherer RM; Nair K; Ghushchyan V; Saseen JJ
Am J Cardiovasc Drugs; 2015 Feb; 15(1):27-34. PubMed ID: 25348907
[TBL] [Abstract][Full Text] [Related]
22. Incidence of potential drug-drug interactions with antidiabetic drugs.
Samardzic I; Bacic-Vrca V
Pharmazie; 2015 Jun; 70(6):410-5. PubMed ID: 26189304
[TBL] [Abstract][Full Text] [Related]
23. [Drug-drug interactions in multicentre polypathological polymedicated patients].
Galindo-Ocaña J; Gil-Navarro MV; García-Morillo JS; Bernabeu-Wittel M; Ollero-Baturone M; Ortiz-Camuñez MA
Rev Clin Esp; 2010 Jun; 210(6):270-8. PubMed ID: 20434722
[TBL] [Abstract][Full Text] [Related]
24. Potential drug-drug interactions among prescriptionsfor elderly patients in primary health care.
Gören Z; J Demirkapu M; Akpinar Acet G; Çali S; Gülçebi Idriz Oğlu M
Turk J Med Sci; 2017 Feb; 47(1):47-54. PubMed ID: 28263519
[TBL] [Abstract][Full Text] [Related]
25. Potentially inappropriate prescribing to hospitalised patients.
Radosević N; Gantumur M; Vlahović-Palcevski V
Pharmacoepidemiol Drug Saf; 2008 Jul; 17(7):733-7. PubMed ID: 18050360
[TBL] [Abstract][Full Text] [Related]
26. Analysis of drug-drug interactions (DDIs) in nursing homes in Central Taiwan.
Liao HL; Chen JT; Ma TC; Chang YS
Arch Gerontol Geriatr; 2008; 47(1):99-107. PubMed ID: 17868936
[TBL] [Abstract][Full Text] [Related]
27. Polypharmacy in older oncology patients and the need for an interdisciplinary approach to side-effect management.
Sokol KC; Knudsen JF; Li MM
J Clin Pharm Ther; 2007 Apr; 32(2):169-75. PubMed ID: 17381667
[TBL] [Abstract][Full Text] [Related]
28. Polypharmacy and drug interactions in older patients with cancer receiving chemotherapy: associated factors.
Oliveira RF; Oliveira AI; Cruz AS; Ribeiro O; Afreixo V; Pimentel F
BMC Geriatr; 2024 Jun; 24(1):557. PubMed ID: 38918696
[TBL] [Abstract][Full Text] [Related]
29. [Prevalence of potential drug-drug interactions in ambulatory patients with statin therapy].
Rätz Bravo AE; Tchambaz L; Krähenbuhl-Melcher A; Hess L; Schlienger RG; Krähenbühl S
Praxis (Bern 1994); 2006 Feb; 95(5):139-46. PubMed ID: 16509450
[TBL] [Abstract][Full Text] [Related]
30. The impact of number of drugs prescribed on the risk of potentially inappropriate medication among outpatient older adults with chronic diseases.
Weng MC; Tsai CF; Sheu KL; Lee YT; Lee HC; Tzeng SL; Ueng KC; Chen CC; Chen SC
QJM; 2013 Nov; 106(11):1009-15. PubMed ID: 23836694
[TBL] [Abstract][Full Text] [Related]
31. Comorbidity ascertainment from the ESRD Medical Evidence Report and Medicare claims around dialysis initiation: a comparison using US Renal Data System data.
Krishnan M; Weinhandl ED; Jackson S; Gilbertson DT; Lacson E
Am J Kidney Dis; 2015 Nov; 66(5):802-12. PubMed ID: 26015277
[TBL] [Abstract][Full Text] [Related]
32. Characterization of drug-drug interactions in patients whose substance intake was objectively identified by detection in urine.
Schrecker J; Puet B; Hild C; Schwope DM
Expert Opin Drug Metab Toxicol; 2018 Sep; 14(9):973-978. PubMed ID: 30092669
[TBL] [Abstract][Full Text] [Related]
33. Factors associated with medication-related problems in ambulatory hemodialysis patients.
Manley HJ; McClaran ML; Overbay DK; Wright MA; Reid GM; Bender WL; Neufeld TK; Hebbar S; Muther RS
Am J Kidney Dis; 2003 Feb; 41(2):386-93. PubMed ID: 12552501
[TBL] [Abstract][Full Text] [Related]
34. Chronic hemodialysis patients. Part I: Characterization and drug-related problems.
Kaplan B; Mason NA; Shimp LA; Ascione FJ
Ann Pharmacother; 1994 Mar; 28(3):316-9. PubMed ID: 8193416
[TBL] [Abstract][Full Text] [Related]
35. Drug-drug interactions associated with length of stay and cost of hospitalization.
Moura CS; Acurcio FA; Belo NO
J Pharm Pharm Sci; 2009; 12(3):266-72. PubMed ID: 20067703
[TBL] [Abstract][Full Text] [Related]
36. [The Veneto Region's Registry of Dialysis and Transplantation: 2006-2007 report].
Antonucci F; Camerin E; Feriani M; Nordio M; Piccoli A; Rossi B; Tessitore N
G Ital Nefrol; 2009; 26 Suppl 48():S5-56. PubMed ID: 19927265
[TBL] [Abstract][Full Text] [Related]
37. Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population.
Goldberg RM; Mabee J; Chan L; Wong S
Am J Emerg Med; 1996 Sep; 14(5):447-50. PubMed ID: 8765105
[TBL] [Abstract][Full Text] [Related]
38. Risk Factors of Ischemic Stroke and Subsequent Outcome in Patients Receiving Hemodialysis.
Findlay MD; Thomson PC; Fulton RL; Solbu MD; Jardine AG; Patel RK; Stevens KK; Geddes CC; Dawson J; Mark PB
Stroke; 2015 Sep; 46(9):2477-81. PubMed ID: 26230856
[TBL] [Abstract][Full Text] [Related]
39. Uptitrating amlodipine significantly reduces blood pressure in diabetic patients with hypertension: a retrospective, pooled analysis.
Jeffers BW; Bhambri R; Robbins J
Vasc Health Risk Manag; 2014; 10():651-9. PubMed ID: 25484592
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of drug-related problems in an outpatient hemodialysis unit and the impact of a clinical pharmacist.
Grabe DW; Low CL; Bailie GR; Eisele G
Clin Nephrol; 1997 Feb; 47(2):117-21. PubMed ID: 9049460
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
